Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide

<table>Clinical course of Case <a href="https://static.hindawi.com/articles/crihem/volume-2013/651902/figures/#casee1">1</a>. mPSL: methylprednisolone; Len: lenalidomide; HDD: high-dose dexamethasone; LDD: low-dose dexamethasone; BD: bortezomib plus dexamethasone; CY: cyclophosphamide; Hb: hemoglobin; PLT: platelet counts; WBC: white blood cell counts; and neut.: neutrophil count. </table>

Case Reports in Hematology

fig1

Figure 1

Figure 1: Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide 

Figure 1 | Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide 